Table 5 Spearman rank correlation of change in ESR1 expression/pre-selected gene signature scores and percentage of 2-week change in Ki67/residual Ki67 level in (i) HER2− tumours, (ii) HER2+ tumours, and (iii) significance of the difference between the two correlation coefficients (HER2− vs HER2+).
Change in gene signature scores | HER2− (n = 135) | HER2+ (n = 22) | Significance of the difference between two correlation coefficients (HER2− vs HER2+) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Change in Ki67 (n = 121) | Residual Ki67 (n = 124) | Change in Ki67 (n = 21) | Residual Ki67 (n = 22) | ||||||||
Signature name | Reference | Rho | p value | Rho | p value | Rho | p value | Rho | p value | Change in Ki67 | Residual Ki67 |
ESR1 | − 0.08 | 3.58E−01 | 0.03 | 7.37E−01 | 0.41 | 6.70E−02 | 0.48 | 2.20E−02 | 3.69E−02 | 4.61E−02 | |
E2F4activation-GS | Guerrero-Zotano et al. | 0.38 | 2.12E−05 | 0.13 | 1.58E−01 | 0.42 | 5.84E−02 | 0.18 | 4.22E−01 | 8.47E−01 | 8.36E−01 |
DiLeoRBloss-GS | Malorni et al. | 0.36 | 4.29E−05 | 0.09 | 3.12E−01 | 0.40 | 7.55E−02 | 0.23 | 2.94E−01 | 8.50E−01 | 5.60E−01 |
JClinInvest2007RBloss-GS | Bosco et al. | 0.35 | 1.05E−04 | 0.08 | 3.87E−01 | 0.38 | 8.53E−02 | 0.22 | 3.31E−01 | 8.89E−01 | 5.62E−01 |
GGI-GS | Sotiriou et al. | 0.34 | 1.30E−04 | 0.08 | 3.75E−01 | 0.41 | 6.28E−02 | 0.24 | 2.77E−01 | 7.42E−01 | 5.05E−01 |
CIN70-GS | Carter et al. | 0.33 | 2.16E−04 | 0.09 | 3.26E−01 | 0.43 | 5.18E−02 | 0.23 | 3.04E−01 | 6.36E−01 | 5.60E−01 |
E2FmotifCellCycleAssociated-GS | Miller et al. | 0.31 | 4.37E−04 | 0.04 | 6.91E−01 | 0.53 | 1.38E−02 | 0.09 | 6.84E−01 | 2.75E−01 | 8.39E−01 |
Gene70-GS | van ‘t Veer et al. | 0.31 | 5.01E−04 | 0.05 | 5.90E−01 | 0.44 | 4.65E−02 | 0.14 | 5.46E−01 | 5.39E−01 | 7.13E−01 |
E2Factivation-GS | Miller et al. | 0.29 | 1.49E−03 | 0.13 | 1.40E−01 | 0.42 | 5.92E−02 | 0.04 | 8.59E−01 | 5.46E−01 | 7.14E−01 |
ERGs-GS | Dunbier et al. | 0.25 | 5.44E−03 | 0.28 | 1.96E−03 | 0.11 | 6.30E−01 | 0.49 | 2.07E−02 | 5.58E−01 | 3.15E−01 |
PTEN-GS | Saale at al. | 0.23 | 1.16E−02 | 0.04 | 6.24E−01 | 0.46 | 3.43E−02 | 0.20 | 3.79E−01 | 2.87E−01 | 5.10E−01 |
PI3K-GS | Creighton 2010 | 0.23 | 1.31E−02 | 0.12 | 1.95E−01 | 0.50 | 1.99E−02 | 0.37 | 9.24E−02 | 2.02E−01 | 2.79E−01 |
AURKA-GS | Desmedt et al. | 0.21 | 2.32E−02 | 0.01 | 8.70E−01 | 0.46 | 3.37E−02 | 0.38 | 7.72E−02 | 2.50E−01 | 1.15E−01 |
E2F3-GS | Bild et al. | 0.20 | 3.20E−02 | 0.07 | 4.34E−01 | 0.43 | 5.18E−02 | 0.33 | 1.36E−01 | 2.98E−01 | 2.70E−01 |
WntTarget34-GS | VerhaeghCR2014TableS1 | 0.17 | 6.11E−02 | 0.16 | 6.99E−02 | 0.11 | 6.26E−01 | − 0.09 | 6.91E−01 | 8.04E−01 | 3.09E−01 |
AKT/mTOR-GS | Majumder et al. | 0.15 | 9.44E−02 | 0.14 | 1.20E−01 | 0.29 | 2.03E−01 | 0.25 | 2.64E−01 | 5.51E−01 | 6.43E−01 |
IGF1-GS | Creighton et al. | 0.13 | 1.61E−01 | − 0.05 | 5.80E−01 | 0.32 | 1.54E−01 | 0.42 | 5.41E−02 | 4.16E−01 | 4.41E−02 |
ERTarget27-GS | VerhaeghCR2014TableS2 | 0.12 | 1.86E−01 | 0.19 | 3.26E−02 | 0.29 | 1.97E−01 | 0.41 | 5.85E−02 | 4.72E−01 | 3.25E−01 |
MacTh1-GS | Iglesia et al. | 0.10 | 2.57E−01 | 0.09 | 3.23E−01 | − 0.17 | 4.51E−01 | − 0.14 | 5.33E−01 | 2.71E−01 | 3.50E−01 |
CASP3-GS | Desmedt et al. | 0.09 | 3.06E−01 | 0.12 | 2.00E−01 | 0.17 | 4.64E−01 | − 0.08 | 7.32E−01 | 7.42E−01 | 4.17E−01 |
STAT1-GS | Desmedt et al. | 0.07 | 4.50E−01 | 0.02 | 8.06E−01 | 0.11 | 6.30E−01 | − 0.22 | 3.18E−01 | 8.70E−01 | 3.24E−01 |
GDNF-GS | Morandi et al. | 0.06 | 4.80E−01 | 0.04 | 6.99E−01 | 0.20 | 3.94E−01 | 0.03 | 8.91E−01 | 5.64E−01 | 9.68E−01 |
MYC-GS | Bild et al. | 0.06 | 5.30E−01 | − 0.10 | 2.60E−01 | 0.40 | 7.14E−02 | 0.43 | 4.41E−02 | 1.41E−01 | 2.34E−02 |
Inflammatory-GS | Dunbier et al. | 0.06 | 5.34E−01 | 0.03 | 7.56E−01 | − 0.19 | 3.97E−01 | − 0.28 | 2.04E−01 | 3.07E−01 | 1.99E−01 |
Bcell-GS | Iglesia et al. | 0.05 | 5.55E−01 | 0.02 | 7.97E−01 | − 0.01 | 9.55E−01 | − 0.54 | 9.42E−03 | 8.08E−01 | 1.16E−02 |
Tcell-GS | Iglesia et al. | 0.05 | 5.61E−01 | − 0.02 | 8.09E−01 | − 0.41 | 6.46E−02 | − 0.33 | 1.36E−01 | 4.95E−02 | 1.92E−01 |
obesity-GS | Creighton et al. | 0.05 | 5.67E−01 | − 0.12 | 1.91E−01 | − 0.22 | 3.33E−01 | 0.23 | 3.06E−01 | 2.68E−01 | 1.51E−01 |
VEGF-GS | Desmedt et al. | 0.03 | 7.41E−01 | − 0.02 | 8.34E−01 | 0.46 | 3.43E−02 | 0.63 | 1.57E−03 | 5.87E−02 | 2.07E−03 |
Stroma.2.PLAU-GS | Desmedt et al. | 0.02 | 8.14E−01 | 0.01 | 9.55E−01 | − 0.21 | 3.51E−01 | − 0.17 | 4.46E−01 | 3.46E−01 | 4.62E−01 |
BetaCatenin-GS | Bild et al. | 0.02 | 8.50E−01 | − 0.07 | 4.09E−01 | − 0.02 | 9.29E−01 | 0.33 | 1.39E−01 | 8.71E−01 | 9.48E−02 |
Stroma.1-GS | Farmer at al. | 0.00 | 9.71E−01 | 0.04 | 6.27E−01 | − 0.20 | 3.88E−01 | − 0.26 | 2.51E−01 | 4.12E−01 | 2.16E−01 |
MAPK-GS | Creighton et al. | − 0.01 | 9.24E−01 | − 0.07 | 4.24E−01 | − 0.27 | 2.36E−01 | − 0.30 | 1.70E−01 | 2.80E−01 | 3.33E−01 |
Immune.1-GS | Teschendorff at al. | − 0.01 | 9.12E−01 | − 0.03 | 7.16E−01 | − 0.16 | 4.78E−01 | 0.03 | 8.79E−01 | 5.40E−01 | 8.08E−01 |
PIK3CA-GS | Loi et al. | − 0.01 | 9.00E−01 | 0.02 | 8.03E−01 | − 0.23 | 3.22E−01 | − 0.15 | 5.13E−01 | 3.64E−01 | 4.89E−01 |
SRC-GS | Bild et al. | − 0.03 | 7.43E−01 | − 0.13 | 1.58E−01 | − 0.06 | 7.97E−01 | − 0.14 | 5.46E−01 | 9.03E−01 | 9.67E−01 |
ESR1.1-GS | Mackay et al. | − 0.05 | 6.16E−01 | 0.07 | 4.16E−01 | 0.31 | 1.71E−01 | 0.42 | 4.99E−02 | 1.34E−01 | 1.27E−01 |
SET-GS | Symmans et al | − 0.05 | 5.70E−01 | 0.09 | 3.21E−01 | 0.22 | 3.28E−01 | 0.45 | 3.36E−02 | 2.68E−01 | 1.11E−01 |
RAS-GS | Bild et al. | − 0.06 | 4.99E−01 | − 0.13 | 1.39E−01 | 0.40 | 7.44E−02 | 0.11 | 6.29E−01 | 5.04E−02 | 3.29E−01 |
ESR1.2-GS | Desmedt et al. | − 0.10 | 2.81E−01 | 0.05 | 5.69E−01 | 0.29 | 1.97E−01 | 0.62 | 2.21E−03 | 1.07E−01 | 6.32E−03 |
ERBB2-GS | Desmedt et al. | − 0.24 | 9.08E−03 | − 0.22 | 1.20E−02 | − 0.04 | 8.80E−01 | 0.15 | 5.06E−01 | 4.08E−01 | 1.29E−01 |
TP53-GS | Coutant et al. | − 0.37 | 2.38E−05 | − 0.12 | 1.82E−01 | − 0.32 | 1.63E−01 | − 0.32 | 1.43E−01 | 8.18E−01 | 3.93E−01 |
PAGs | Gao et al. | 0.27 | 3.11E−03 | 0.07 | 4.68E−01 | 0.47 | 2.99E−02 | 0.11 | 6.12E−01 | 3.45E−01 | 8.70E−01 |